Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

67.57 +0.27 (+0.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
66 67 Next >
A Look Into AstraZeneca's Debt
Via Benzinga
Stock Market Rally Pulls Back As Yields Jump; Tesla, Meta In Focus: Weekly Review
Automakers rallied on sales while Meta's Threads had a big launch. 
Via Investor's Business Daily
Biotech Blues: Stay Balanced Through July Earnings Season
Life Science stocks lack momentum so be prepared for rebalancing and rotation shifts. 
Via Talk Markets
These Were Monday's 2 Stock Movers That Investors Cared About the Most
On a quiet day on Wall Street, a couple of stocks still saw a considerable amount of activity. 
Via The Motley Fool
AstraZeneca Losses Leave The FTSE In The Red To Start July
Despite reaching record highs earlier this year, the UK's FTSE 100 experienced a decline in the April-June period due to volatile commodity prices and persistent inflation concerns. 
Via Talk Markets
AstraZeneca Unusual Options Activity
Via Benzinga
AstraZeneca Plummets, Sacrificing A Breakout, On Mixed Results In Lung Cancer Treatment
The company tested a treatment in combination with Daiichi Sankyo. 
Via Investor's Business Daily
AstraZeneca Unusual Options Activity For June 28
Via Benzinga
Price Over Earnings Overview: AstraZeneca
Via Benzinga
AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today’s session. Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares... 
Via Benzinga
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial
From AstraZeneca
Via Business Wire
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung... 
Via Benzinga
4 Unparalleled Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Bargains abound with the innovation-driven Nasdaq Composite still well below its all-time high. 
Via The Motley Fool
Week In Review: AstraZeneca Considers Spinning Off China Ops Into Separate Company
Deals, financings, trials and approvals for the week ending June 23. 
Via Talk Markets
This Is What Whales Are Betting On AstraZeneca
Via Benzinga
Is AstraZeneca a Top Stock to Buy Right Now?
The pharma specialist's top-shelf clinical pipeline and product portfolio should be tremendous growth drivers in the years ahead. 
Via The Motley Fool
AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer
AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)... 
Via Benzinga
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Phase III trial
From AstraZeneca
Via Business Wire
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
From AstraZeneca
Via Business Wire
$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,100 Today
Via Benzinga
What Does AstraZeneca's Debt Look Like?
Via Benzinga
Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead
After a huge run-up in stocks since January investors have come to realize that most of the gains have come from the so-called “Magnificent Seven” tech stocks. 
Via Talk Markets
Post-COVID-19: How the COVAX Initiative Could Redirect its $2.6B Surplus to Fight Future Pandemics
As the emergency phase of the COVID-19 pandemic draws to a close, the COVAX initiative, run by Gavi, the WHO, and CEPI, reportedly has $2.6 billion left over that could be used to prepare for other... 
Via Benzinga
AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease
The European Union has reco 
Via Benzinga
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials
ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles t 
Via MarketBeat
Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst
Raymond James has initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN) with an Outperform rating and a  
Via Benzinga
AI Stocks: C3.ai, Palantir Pull Back Amid HPE, Cybersecurity, Cloud AI News
The big rally in AI stocks may finally be taking a break but the steady drumbeat in artificial intelligence news continues. 
Via Investor's Business Daily
European Drug Authority Raises Thyroid Cancer Safety Signal For Novo Nordisk Drugs, Including Hyped Semaglutide
The EU's drugs watchdog, the European Medicines Agency, recently raised a thyroid cancer safety signal for Novo Nordisk A/S (NYSE: NVO) drugs, including the much talked semaglutide used i 
Via Benzinga
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult... 
Via Benzinga
Why Are Pieris Pharmaceuticals Shares Tanking Today
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) announced that partner AstraZeneca plc (NASDAQ: AZN) decided to discontinue and cease dosing in the ongoing clinical studies of elarekibep, an inhaled IL-4... 
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.